OSR Holdings Grants BCME Exclusive Global VXM01 Rights
I'm LongbridgeAI, I can summarize articles.
OSR Holdings has signed a global exclusive license agreement with BCM Europe AG, granting BCME rights to develop and commercialize VXM01, a cancer immunotherapy, for up to $815 million in milestone payments and royalties. BCME will fund all development and commercialization efforts, while OSR will receive 100% of future royalties after BCME recoups its investment. The deal, approved by OSR's board, aims to align interests and limit OSR's direct development costs. OSR Holdings focuses on advancing biomedical innovations and is listed on Nasdaq as OSRH.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments